These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38054211)

  • 1. Recurrent heart failure hospitalizations in heart failure with preserved ejection fraction: an analysis of TOPCAT trial.
    Wang Q; Yu F; Su H; Liu Z; Hu K; Wu G; Yan J; Chen K; Yang D
    ESC Heart Fail; 2024 Feb; 11(1):475-482. PubMed ID: 38054211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Impact of Cardiovascular Versus Noncardiovascular Hospitalizations in Heart Failure With Preserved Ejection Fraction: Insights From TOPCAT.
    Barkoudah E; Claggett BL; Lewis EF; O'Meara E; Clausell N; Diaz R; Fleg JL; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
    J Card Fail; 2022 Sep; 28(9):1390-1397. PubMed ID: 35636727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial.
    Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD
    JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial.
    Merrill M; Sweitzer NK; Lindenfeld J; Kao DP
    JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term events following catheter-ablation for atrial fibrillation in heart failure with preserved ejection fraction.
    Ishiguchi H; Yoshiga Y; Shimizu A; Ueyama T; Fukuda M; Kato T; Fujii S; Hisaoka M; Uchida T; Omuro T; Okamura T; Kobayashi S; Yano M
    ESC Heart Fail; 2022 Oct; 9(5):3505-3518. PubMed ID: 35894764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
    Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial Infarction in Heart Failure With Preserved Ejection Fraction: Pooled Analysis of 3 Clinical Trials.
    Cunningham JW; Vaduganathan M; Claggett BL; John JE; Desai AS; Lewis EF; Zile MR; Carson P; Jhund PS; Kober L; Pitt B; Shah SJ; Swedberg K; Anand IS; Yusuf S; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2020 Aug; 8(8):618-626. PubMed ID: 32387067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial Fibrillation can adversely impact Heart Failure with Preserved Ejection Fraction by its association with Heart Failure Progression and Mortality: A Post-Hoc Propensity Score-Matched Analysis of the TOPCAT Americas Trial.
    Saksena S; Slee A; Natale A; Lakkireddy DR; Shah D; Di Biase L; Lewalter T; Nagarakanti R; Santangeli P
    Europace; 2023 May; 25(5):. PubMed ID: 37078691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
    Joseph J; Claggett BC; Anand IS; Fleg JL; Huynh T; Desai AS; Solomon SD; O'Meara E; Mckinlay S; Pitt B; Pfeffer MA; Lewis EF
    JACC Heart Fail; 2016 Jun; 4(6):477-86. PubMed ID: 27039126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diuretic and renal effects of spironolactone and heart failure hospitalizations: a TOPCAT Americas analysis.
    Kalogeropoulos AP; Thankachen J; Butler J; Fang JC
    Eur J Heart Fail; 2020 Sep; 22(9):1600-1610. PubMed ID: 32469156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
    JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; O'Meara E; Desai AS; Heitner JF; Li G; Fang J; Rouleau J; Zile MR; Markov V; Ryabov V; Reis G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2014 Sep; 7(5):740-51. PubMed ID: 25122186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.
    Cikes M; Claggett B; Shah AM; Desai AS; Lewis EF; Shah SJ; Anand IS; O'Meara E; Rouleau JL; Sweitzer NK; Fang JC; Saksena S; Pitt B; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2018 Aug; 6(8):689-697. PubMed ID: 30007557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
    Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
    Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent heart failure hospitalizations increase the risk of mortality in heart failure patients with atrial fibrillation and type 2 diabetes mellitus in the United Kingdom: a retrospective analysis of Clinical Practice Research Datalink database.
    Lahoz R; Fagan A; McSharry M; Proudfoot C; Corda S; Studer R
    BMC Cardiovasc Disord; 2022 May; 22(1):234. PubMed ID: 35597922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone for Management of Heart Failure with Preserved Ejection Fraction: Whither to After TOPCAT?
    Mitter SS; Shah SJ
    Curr Atheroscler Rep; 2015 Nov; 17(11):64. PubMed ID: 26408016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Liu L; Pitt B; Pfeffer MA; Solomon SD
    Circulation; 2015 Aug; 132(5):402-14. PubMed ID: 26130119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT).
    Fudim M; Kelly JP; Brophy TJ; DeVore AD; Hammill BG; Peterson ED; Pitt B; Yancy C; Fonarow GC; Hernandez AF
    Am J Cardiol; 2020 Jun; 125(11):1655-1660. PubMed ID: 32273054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analysis Evaluating the Effects of Renin-Angiotensin-Aldosterone System Blockade on Outcomes of Heart Failure With Preserved Ejection Fraction.
    Kuno T; Ueyama H; Fujisaki T; Briasouli A; Takagi H; Briasoulis A
    Am J Cardiol; 2020 Apr; 125(8):1187-1193. PubMed ID: 32081366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.